ImmuPharma PLC (IMM)

Back to homepage

Company Description

ImmuPharma PLC is a drug discovery and development company incorporated in United Kingdom on February 21, 2000. The Company along with its subsidiaries is engaged in pharmaceutical research and development of novel drugs, based on peptide therapeutics, to treat serious medical conditions including autoimmune diseases. The Company is currently developing drug candidates for five different medical conditions including; Lupus, Cancer, Moderate to severe pain Including cancer and post-operative pain, Severe resistant hospital-acquired infections including MRSA, and Inflammation/allergic conditions including asthma and rheumatoid arthritis. The product candidate targets Lupus, a disease for which there is currently no cure or specific treatment, and is successfully licensed to Cephalon, Inc. The Company has collaboration with the Centre National de la Recherche Scientifique, French National Council for Scientific Research, and Institut National de la Sante et de la Recherche Medicale for health and medical research. The Company faces competition from others, major pharmaceutical, biotechnology and healthcare companies...